Skip to main content

PharmaCyte Biotech, Inc.

PMCB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001157075

No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.

Q2 2022 vs. Q1 2022

How the institutions holding PharmaCyte Biotech, Inc. changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of PMCB: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders28135+8
Shares3.84M34.8K3.92M+116.8K (+3.1%)
Value$8.83M$80.0K$8.79M+$44.0K (+0.5%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (9)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to PMCB in Q2 2022
InstitutionSharesValue% of portfolio
K2 Principal Fund, L.P.91,095$204.0K0.03%
Group One Trading, L.P.69,041$156.0K0.00%
Simplex Trading, LLC54,927$123.0K0.00%
Citadel Advisors LLC31,696$72.0K0.00%
Millennium Management LLC17,519$40.0K0.00%
BlackRock Inc.8,881$20.0K0.00%
Tower Research Capital LLC (TRC)1,161$2.00K0.00%
CWM, LLC1$00.00%
Heritage Financial Services, LLC67$00.00%

Sold out (1)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of PMCB in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
JPMorgan Chase & Co2,723$6.00K

Not filed for Q2 2022 yet (1)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PMCB in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Susquehanna Fundamental Investments, LLC34,805$80.0K